Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Tuoyi (toripalimab) is an anti-PD-1 monoclonal antibody. It is approved by NMPA for the treatment of recurrent or metastatic triple-negative breast cancer.
Lead Product(s): Toripalimab,Paclitaxel
Therapeutic Area: Oncology Product Name: Tuoyi
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 25, 2024
Details:
Tuoyi (toripalimab) is an anti-PD-1 monoclonal antibody, which is being evaluated in combination with etoposide & cisplatin for the first-line treatment of small cell lung cancer.
Lead Product(s): Toripalimab,Etoposide,Cisplatin
Therapeutic Area: Oncology Product Name: Tuoyi
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 18, 2024
Details:
Tuoyi (toripalimab) is an anti-PD-1 monoclonal antibody, which is being evaluated in combination with bevacizumab for the first-line treatment of advanced hepatocellular carcinoma.
Lead Product(s): Toripalimab,Bevacizumab
Therapeutic Area: Oncology Product Name: Tuoyi
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 11, 2024
Details:
Loqtorzi (toripalimab) is an anti-PD-1 monoclonal antibody, which is an approved product in combination with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent locally advanced nasopharyngeal carcinoma.
Lead Product(s): Toripalimab,Cisplatin,Gemcitabine
Therapeutic Area: Oncology Product Name: Loqtorzi
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 24, 2024
Details:
JS001 (toripalimab) is an anti-PD-1 monoclonal antibody developed for its ability to block PD-1 interactions. It is approved in combination with axitinib for the treatment of renal carcinoma.
Lead Product(s): Toripalimab,Axitinib
Therapeutic Area: Oncology Product Name: Tuoyi
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 07, 2024
Details:
Loqtorzi (toripalimab-tpzi) is an anti-PD-1 monoclonal antibody, which is an approved product in combination with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent locally advanced nasopharyngeal carcinoma.
Lead Product(s): Toripalimab,Cisplatin,Gemcitabine
Therapeutic Area: Oncology Product Name: Loqtorzi
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 01, 2024
Details:
Tuoyi (toripalimab) is an anti-PD-1 monoclonal antibody developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2. It is under phase 3 clinical development for the treatment of advanced triple-negative breast cancer.
Lead Product(s): Toripalimab,Paclitaxel
Therapeutic Area: Oncology Product Name: Tuoyi
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2024
Details:
Tuoyi (toripalimab) is an anti-PD-1 monoclonal antibody developed for its ability to block PD-1 interactions. It is under phase 3 clinical development for the treatment of adult patients with resectable stage IIIA-IIIB non-small cell lung cancer (NSCLC).
Lead Product(s): Toripalimab,Cisplatin,Carboplatin
Therapeutic Area: Oncology Product Name: Tuoyi
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 02, 2024
Details:
JS001 (toripalimab) is an anti-PD-1 monoclonal antibody developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2. It is being developed for the treatment of metastatic or recurrent locally advanced nasopharyngeal carcinoma.
Lead Product(s): Toripalimab,Gemcitabine,Cisplatin
Therapeutic Area: Oncology Product Name: JS001
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 01, 2023
Details:
Loqtorzi (toripalimab-tpzi) is a next generation anti-PD-1 monoclonal antibody that blocks PD-L1 binding to the PD-1 receptor at a unique site with high affinity and activates antitumor immunity. It is approved for treatment of recurrent/metastatic nasopharyngeal carcinoma.
Lead Product(s): Toripalimab
Therapeutic Area: Oncology Product Name: Loqtorzi
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: Coherus Biosciences
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2023